TrialCancer chemotherapy and pharmacology2019

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.

F J Esteva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.